Konakion (Phytomenadione)

Konakion (phytomenadione) is used to address disorders of the coagulation cascade related to vitamin K deficiency.

• Vitamin K deficiency bleeding: prevents and treats bleeding caused by insufficient vitamin K.
• Newborn hemorrhage prophylaxis: reduces risk of hemorrhagic disease of the newborn.
• Anticoagulant reversal: restores clotting factor activity after warfarin or other vitamin K antagonist therapy.

• Phytomenadione acts as a cofactor for the γ‑carboxylation of glutamic acid residues on clotting factors II, VII, IX and X in the liver. This post‑translational modification generates functional vitamin K‑dependent clotting proteins, enabling normal thrombin generation and hemostasis. The administered form is rapidly taken up by hepatic cells and converted to the active hydroquinone, which participates in the enzymatic cycle that recycles vitamin K and sustains the synthesis of these factors.

Phytomenadione may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site pain: discomfort or soreness at the site of intramuscular or intravenous administration.
• Nausea: mild gastrointestinal upset following oral intake.
• Headache: transient headache reported in some patients.
• Fever: low‑grade pyrexia occurring after injection.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Hemolysis: rare destruction of red blood cells.
• Thrombosis: unexpected clot formation in veins or arteries.
• Hyperbilirubinemia: elevated bilirubin levels, particularly in neonates.

When using Konakion, several precautions should be observed to ensure safety and efficacy.

• Contraindication: do not use in patients with known hypersensitivity to phytomenadione or any excipients.
• Bleeding disorders: monitor coagulation parameters in patients with existing coagulopathies.
• Liver disease: assess hepatic function as synthesis of clotting factors may be impaired.
• Neonates: adjust dosing and monitor for hyperbilirubinemia in newborns.
• Drug interactions: review concurrent anticoagulant or vitamin K antagonist therapy.
• Store at room temperature: keep in original container, protect from moisture and light.

Phytomenadione can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Warfarin: may reduce anticoagulant effect, requiring dose adjustment and INR monitoring.
• Broad‑spectrum antibiotics (e.g., cephalosporins): can impair vitamin K synthesis, potentially altering response.

Moderate Interactions (Monitor Closely)

• Rifampin: may increase metabolism of vitamin K, decreasing its effectiveness.
• Cholestyramine or other bile‑acid sequestrants: can reduce absorption of oral phytomenadione.
• Heparin: concurrent use may increase bleeding risk; monitor coagulation status.